Salix Pharmaceuticals Company Profile (NASDAQ:SLXP)

About Salix Pharmaceuticals (NASDAQ:SLXP)

Salix Pharmaceuticals logoSalix Pharmaceuticals, Ltd. is a specialty pharmaceutical company engaged in acquiring, developing and commercializing prescription drugs and medical devices used in the treatment of a variety of gastrointestinal disorders. The Company offers over 20 marketed products, such as XIFAXAN550 (rifaximin) tablets, XIFAXAN (rifaximin) tablets, APRISO (mesalamine) extended-release capsules, UCERIS (budesonide MMX) extended release tablets, MOVIPREP, GLUMETZA extended release tablets, RELISTOR subcutaneous injection, UCERIS rectal foam, OSMOPREP tablets, SOLESTA, DEFLUX, FULYZAQ (crofelemer) delayed-release tablets, GIAZO (balsalazide disodium) tablets, CYCLOSET (bromocriptine mesylate) tablets, and FENOGLIDE (fenofibrate) tablets, among others. Its primary product candidates under development include Rifaximin, Methylnaltrexone bromide oral, Ruconest, Rifaximin delayed release or extended intestinal release and Rifaximin soluble solid dispersion (SSD)/next generation.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Specialty & Advanced Pharmaceuticals
  • Sub-Industry: Pharmaceuticals
  • Symbol: NASDAQ:SLXP
  • CUSIP: 79543510
  • Web:
Average Prices:
  • 50 Day Moving Avg: $163.00
  • 200 Day Moving Avg: $136.00
  • 52 Week Range: $86.00 - $173.00
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: 18.78
  • P/E Growth: 0
  • Net Margins: -2,134.34%
  • Return on Equity: -305.24%
  • Return on Assets: -25.83%
  • Average Volume: 3.35 million shs.

Frequently Asked Questions for Salix Pharmaceuticals (NASDAQ:SLXP)

What is Salix Pharmaceuticals' stock symbol?

Salix Pharmaceuticals trades on the NASDAQ under the ticker symbol "SLXP."

How were Salix Pharmaceuticals' earnings last quarter?

Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) released its quarterly earnings results on Monday, March, 2nd. The company reported ($2.61) earnings per share for the quarter, missing analysts' consensus estimates of ($0.29) by $2.32. The firm had revenue of $13 million for the quarter, compared to analyst estimates of $187.97 million. Salix Pharmaceuticals had a negative return on equity of 305.24% and a negative net margin of 2,134.34%. During the same period last year, the company earned $1.06 EPS. View Salix Pharmaceuticals' Earnings History.

Who are some of Salix Pharmaceuticals' key competitors?

How do I buy Salix Pharmaceuticals stock?

Shares of Salix Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Salix Pharmaceuticals' stock price today?

One share of Salix Pharmaceuticals stock can currently be purchased for approximately $169.00.

MarketBeat Community Rating for Salix Pharmaceuticals (NASDAQ SLXP)
Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  305 (Vote Outperform)
Underperform Votes:  256 (Vote Underperform)
Total Votes:  561
MarketBeat's community ratings are surveys of what our community members think about Salix Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Salix Pharmaceuticals (NASDAQ:SLXP) (How are Consensus Ratings Calculated?)
Ratings Breakdown: No ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Consensus Price Target: N/A

Analysts' Ratings History for Salix Pharmaceuticals (NASDAQ:SLXP)
No equities research coverage for this company has been tracked by


Earnings History for Salix Pharmaceuticals (NASDAQ:SLXP)
Earnings by Quarter for Salix Pharmaceuticals (NASDAQ:SLXP)
Earnings History by Quarter for Salix Pharmaceuticals (NASDAQ SLXP)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/2/2015Q414($0.29)($2.61)$187.97 million$13.00 millionViewN/AView Earnings Details
11/6/2014Q314$1.56$1.53$394.00 million$354.70 millionViewN/AView Earnings Details
8/7/2014Q214$1.69$1.59$397.06 million$382.00 millionViewListenView Earnings Details
5/8/2014Q114$0.91$1.05$372.91 million$384.00 millionViewListenView Earnings Details
2/27/2014Q413$0.93$1.06$247.29 million$257.60 millionViewListenView Earnings Details
11/7/2013Q313$0.86$0.89$239.70 million$238.20 millionViewN/AView Earnings Details
8/8/2013Q2 2013$0.81$0.87$226.34 million$235.40 millionViewListenView Earnings Details
5/9/2013Q1 2013$0.67$0.63$205.94 million$202.60 millionViewListenView Earnings Details
2/28/2013Q4 2012$0.78$0.81$199.41 million$198.17 millionViewN/AView Earnings Details
11/7/2012Q312$0.69$0.95$187.23 million$185.13 millionViewN/AView Earnings Details
8/8/2012$0.54$0.79ViewN/AView Earnings Details
5/7/2012$0.56$0.67ViewN/AView Earnings Details
11/8/2011$0.60$0.77ViewN/AView Earnings Details
8/8/2011$0.44$0.32ViewN/AView Earnings Details
5/5/2011$0.17$0.34ViewN/AView Earnings Details
2/28/2011$0.49$0.66ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Salix Pharmaceuticals (NASDAQ:SLXP)
Current Year EPS Consensus Estimate: $4 EPS
Next Year EPS Consensus Estimate: $9 EPS


Dividend History for Salix Pharmaceuticals (NASDAQ:SLXP)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for Salix Pharmaceuticals (NASDAQ:SLXP)
Insider Trades by Quarter for Salix Pharmaceuticals (NASDAQ:SLXP)
Insider Trades by Quarter for Salix Pharmaceuticals (NASDAQ:SLXP)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
3/6/2015Timothy J CreechInsiderSell4,600$157.67$725,282.00View SEC Filing  
3/6/2015William P ForbesEVPSell20,000$157.96$3,159,200.00View SEC Filing  
11/12/2014William P ForbesEVPSell11,079$95.05$1,053,058.95View SEC Filing  
6/26/2014Carolyn J LoganCEOSell53,057$123.38$6,546,172.66View SEC Filing  
4/22/2014Alonzo Thomas DDirectorSell11,530$110.89$1,278,561.70View SEC Filing  
1/10/2014Alonzo Thomas DDirectorSell12,050$91.83$1,106,551.50View SEC Filing  
1/9/2014Adam DerbyshireCFOSell30,001$91.48$2,744,491.48View SEC Filing  
1/8/2014William ForbesEVPSell8,000$90.06$720,480.00View SEC Filing  
1/7/2014Rick ScruggsEVPSell8,463$88.31$747,367.53View SEC Filing  
1/7/2014William KeaneDirectorSell22,500$88.31$1,986,975.00View SEC Filing  
7/24/2013William P ForbesEVPSell12,000$70.93$851,160.00View SEC Filing  
4/10/2013William P ForbesEVPSell8,673$49.37$428,186.01View SEC Filing  
12/26/2012Adam C DerbyshireCFOSell60,000$41.44$2,486,400.00View SEC Filing  
11/13/2012Mark A SirgoDirectorSell3,450$40.53$139,828.50View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Salix Pharmaceuticals (NASDAQ:SLXP)
Latest Headlines for Salix Pharmaceuticals (NASDAQ:SLXP)
DateHeadline logoMallinckrodt PLC (MNK) and Salix Pharmaceuticals (SLXP) Critical Review - September 11 at 12:08 AM logoSalix Pharmaceuticals (SLXP) versus AbbVie (ABBV) Head to Head Survey - September 3 at 10:24 PM logoHead to Head Analysis: AbbVie (ABBV) and Salix Pharmaceuticals (SLXP) - August 15 at 12:16 PM logoFinancial Comparison: Salix Pharmaceuticals (SLXP) versus Novan (NOVN) - July 31 at 9:41 AM logoReviewing Salix Pharmaceuticals (SLXP) and Rockwell Medical (RMTI) - June 29 at 8:10 AM logoSomewhat Favorable Media Coverage Extremely Likely to Impact Salix Pharmaceuticals (SLXP) Stock Price - May 4 at 2:32 PM logoValeant Pharmaceuticals Intl Inc (VRX) To Retain Salix Pharmaceuticals, Ltd. (SLXP) After Negotiations With Takeda Pharmaceutical Co Ltd (ADR) (TKPYY) Collapse - April 24 at 11:31 AM logoSalix Pharmaceuticals (SLXP) Getting Very Favorable Press Coverage, Study Finds - April 19 at 10:29 AM logoBill Ackman To Investors: 'Deeply And Profoundly' Sorry For The Valeant Fiasco - March 31 at 1:09 AM logoValeant stock falls 5% after company files 10-K - March 1 at 8:14 PM logoBill Ackman's nightmare stock is getting stomped for the 2nd day in a row - March 1 at 8:14 PM logo[$$] Allergan Admits to Disclosure Violations During Valeant Bid - February 9 at 4:24 AM logoValeant Pharmaceuticals: We Were Wrong, Morgan Stanley Says - December 16 at 3:56 AM logoWhy Valeant is Crumbling - December 1 at 1:11 AM logoValeant: First No Salix Sale, Now the SEC Sees Accounting Issues?!?! - November 30 at 8:09 PM logoValeant, Salix, Sales Force and Asset Sales - November 30 at 8:09 PM logoUh Oh, Valeant's Hiring. Why That's Very Bad News. - November 30 at 10:42 AM logoValeant's Asset Sale Clock is Ticking - November 21 at 12:47 PM logoIs Valeant Pharmaceuticals the Turnaround Opportunity of a Lifetime? - November 18 at 7:07 PM logo[$$] New Valeant chief nurses $1.3m paper loss on shares - November 13 at 11:23 AM logoAckman: Valeant Can Sell Non-Core Assets to Reduce Debt - November 10 at 7:29 PM logoSelling Salix Could Be the Most "Valeant" Move Ever - November 9 at 7:34 PM logoValeant Pharmaceuticals Just Delivered a Trifecta of Bad News in Its Q3 Report - November 9 at 10:15 AM logoValeant's Possible Fire Sale Looks Worse Than Ever - November 8 at 7:24 PM logoValeant adj profit misses estimates; FY forecast cut - November 8 at 11:22 AM logo[$$] Valeant shares fall after sales and earnings targets cut - November 8 at 11:22 AM logoAnalysts Remain Wary Ahead of Valeant Earnings - November 7 at 8:23 PM logoValeant earnings: Expect an update on plans to sell Salix - November 7 at 8:23 PM logo[$$] Valeant: I love you, you pay my rent - November 2 at 7:51 PM logoNegative Analyst Commentary Pushes Valeant Pharmaceuticals Intl. Inc. Lower by 11% - November 2 at 7:51 PM logoValeant: A Good Strategic Move? - November 2 at 7:51 PM logoValeant: Selling Salix a Warning of Trouble to Come? - November 2 at 11:02 AM logoHold the Valeant Applause - November 2 at 11:02 AM logoValeant gets new approval for legacy Salix drug - July 20 at 1:50 PM logoValeant's Drug Approvals May Save the Day - July 20 at 12:30 PM logoHow Much Is Valeant Pharmaceuticals Really Worth? - June 17 at 2:41 PM logoDetails of kickbacks and fraud emerge in Valeant's Salix unit settlement - June 10 at 11:55 AM



Salix Pharmaceuticals (SLXP) Chart for Friday, September, 22, 2017

This page was last updated on 9/22/2017 by Staff